Form 4: Nurix Therapeutics CFO Hans van Houte Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Hans van Houte, CFO of Nurix Therapeutics, sold shares of common stock on March 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 3, 2025, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, sold shares of the company's common stock.
- The sales were executed under a Rule 10b5-1 trading plan.
- A total of 5,125 shares were sold at a weighted average price of $14.3994, with prices ranging from $13.87 to $14.84.
- An additional 700 shares were sold at a weighted average price of $15.1297, with prices ranging from $14.87 to $15.39.
- Following these transactions, van Houte directly owns 33,724 shares of Nurix Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document simply reports insider trading activity. It's neutral as it doesn't indicate positive or negative performance of the company, but rather a routine transaction under a pre-arranged plan.
Industry Context
Sales by insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.
Stakeholder Impact
- Shareholders may interpret insider sales as a lack of confidence in the company's future prospects, although sales under 10b5-1 plans are often pre-scheduled and may not reflect current sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of stock sale transactions |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.